Skip to main content
OpenTrials
Completed

NCT Number: NCT03176355

Intraoperative Mitomycin C in Lacrimal Sac Mucocele

30 patients had lacrimal sac mucocele and dacryocystorhinostomy was done for them with intraoperative mitomycin C was added to decrease postoperative fibrosis and recurrence.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lacrimal Mucocele

Age range

20 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Lacrimal sac mucocele

Exclusion criteria

  • Paediatric patients (less than 16 years old).
  • Previous lacrimal passage procedure.
  • Neoplasms as secondary causes of obstruction.

Treatment and study plan

Canaliculo- Dacryocystorhinostomy

Procedure

Bypass lacrimal passage obstruction by opening a shunt between the lacrimal sac and the nasal mucosa

Primary outcomes

  1. Disappearance of the watering of the eye reported by the patients and by fluorescein disappearance test

    Time frame: 1 month

    Patency of the lacrimal passage

  2. Disappearance of lacrimal sac swelling

    Time frame: 1 month

    No evident swelling in the medial side of the eye

Sponsors and collaborators

Lead sponsor

Minia University

Other

Registry information

Official study title

Evaluation of Intraoperative Mitomycin C in Surgical Management of Lacrimal Sac Mucocele

Important dates

Study start
2011
Primary completion
2012
Study completion
2013
First posted
Jun 5, 2017
Registry last updated
Jun 5, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.